A2B Adenosine Receptor Antagonists with Picomolar Potency
- 5 March 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (8) , 4032-4055
Abstract
The A2B adenosine receptor (A2BAR) was proposed as a novel target for the (immuno)therapy of cancer since A2BAR blockade results in antiproliferative, anti-angiogenic, anti-metastatic, and immu-no-stimulatory effects. In this study, we explored the structure-activity relationships of xan-thin-8-yl-benzenesulfonamides mainly by introducing a variety of linkers and substituents attached to the sulfonamide residue. A new, convergent strategy was established which facilitated the synthesis of the target compounds. Many of the new compounds exhibited subnanomolar affinity for the A2BAR combined with high selectivity. Functional groups were introduced which will allow the attachment of dyes and other reporter groups. 8 (4-((4-(4-Bromophenyl)piperazin-1-yl)sulfonyl)phenyl)-1-propylxanthine (34, PSB-1901) was the most potent A2B-antagonist (Ki 0.0835 nM, KB 0.0598 nM, human A2BAR) with >10,000-fold selectiv-ity versus all other AR subtypes. It was similarly potent and selective at the mouse A2BAR, making it a promising tool for preclinical studies. Computational studies predicted halogen bonding to contribute to the outstanding potency of 34.Keywords
Funding Information
- Deutscher Akademischer Austauschdienst (IPID4All)
- Bundesministerium f?r Bildung und Forschung (D11B)
- Alexander von Humboldt-Stiftung
This publication has 73 references indexed in Scilit:
- A2B adenosine receptor blockade inhibits growth of prostate cancer cellsPurinergic Signalling, 2013
- The A 2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung diseaseThe FASEB Journal, 2012
- Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapyPurinergic Signalling, 2011
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisProceedings of the National Academy of Sciences, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidatesPurinergic Signalling, 2008
- ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteinsNucleic Acids Research, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences, 2006
- Comparative Protein Modelling by Satisfaction of Spatial RestraintsJournal of Molecular Biology, 1993